echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > vTv Therapeutics' breakthrough type 1 diabetes therapy mechanism research achieves positive results

    vTv Therapeutics' breakthrough type 1 diabetes therapy mechanism research achieves positive results

    • Last Update: 2021-10-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On October 12, vTv Therapeutics announced that the study of the mechanism of TTP399 in the treatment of type 1 diabetes has obtained positive results, proving that patients with type 1 diabetes who received TTP399 did not have an increase in keto acid levels during the withdrawal of insulin treatment compared with the placebo group, which means that TTP399 does not Increase the risk of ketoacidosis


    The mechanism study enrolled 23 patients with type 1 diabetes who are using insulin pumps and were randomized to receive TP399 (n=12) or placebo (n=11) once a day for approximately 7 days


    Consistent with previous studies, TTP399 can improve fasting blood glucose control, and there were no hypoglycemia events in the TTP399 treatment group one week before the insulin withdrawal test, and 4 hypoglycemia events in the placebo control group


    The FDA previously refused to approve SGLT-2 inhibitors as an adjuvant therapy for T1D patients, mainly because of concerns about the risk of diabetic ketoacidity (DKA)


    TTP399 is a selective glucokinase agonist.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.